401 Study: Trial of Assessing the Efficacy and Safety of ITI-007 Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar 1 or Bipolar 2 Disorder (Bipolar Depression)

401 Study: Trial of Assessing the Efficacy and Safety of ITI-007 Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar 1 or Bipolar 2 Disorder (Bipolar Depression)

Brief description of study

We are looking for people who are currently experiencing major depressive episodes associated with bipolar I or bipolar II disorder to take part in our bipolar depression studies. These clinical research studies are designed to help us learn more about an investigational medication for symptoms of bipolar depression.

Detailed description of study

The 401 Study is a randomized, double-blind, placebo-controlled study which is looking at whether an investigational medication, called ITI-007, can improve the symptoms of bipolar depression (bipolar I or bipolar II disorder). It also aims to look at how safe the investigational medication is and whether it impacts the quality of life and well-being of people with bipolar depression.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Bipolar disorder,Depression,Major depression,Depression,depression
  • Age: Between 18 Years - 75 Years
  • Gender: All
Updated on 30 Jan 2019. Study ID: 824333

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center